Patients in the tirzepatide group also had lower prevalence rates of CKD or anemia, and fewer were using statins, biguanides, sulfonylureas, dipeptidyl peptidase 4 inhibitors, β-blockers, ARBs, or calcium channel blockers. Here, DPP4 is linked to chronic kidney disease.